Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-yearReaffirmed full-year 2026 ...
The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...
The study is testing GLK-321, an eye drop drug, in several dose levels. It aims to lower signs and symptoms of Demodex blepharitis and could become a new product in Glaukos’ growing eye care pipeline ...
Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.
29d
Eye Doctors Share 6 Health Concerns They Can Spot In Your Eye Before You Realize Anything Is Wrong
Glaucoma, an eye condition that affects the optic nerve, is sneaky. “Glaucoma is often referred to as a ‘silent thief of sight’ because in early stages, patients don’t typically notice any symptoms,” ...
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Live webcasts and additional information can be ...
Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results